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ABSTRACT 
Context: Suboptimal drug use is a major contributor to adverse patient outcomes in 
primary care.  Considering their accessibility and frequent interactions with patients, 
community pharmacists may be well suited to identifying patients who are at high risk of 
drug therapy problems (DTPs) and who may benefit from a comprehensive medication 
assessment. 
 
Objective: To determine if a short screening tool can identify patients at risk for DTPs in 
a community pharmacy setting. 
 
Design: A five question self-administered screening tool was identified in the literature 
and adapted to reflect current practice in community pharmacy.  Adults requesting a 
refill prescription from three different community pharmacies over 12 weeks completed 
the screening tool, and had a comprehensive medication assessment with a 
pharmacist.  Information from the assessment was used to: a) determine the ability of 
patients to correctly answer the screening tool questions and to classify themselves into 
the appropriate risk category (High or Low Risk); b) compare the number of DTPs 
identified in each risk category (High vs Low); and c) determine the number of High Risk 
and Low Risk patients who would qualify for any of the existing provincial medication 
review programs in Canada. 
 
Results: 49 patients completed the study.  Most patients were able to answer the 
questions on the screening tool correctly.  The strength of agreement was very good 
(Kappa 0.91, p<0.01) between the overall patient determined risk category and 
pharmacist determined risk category. Patients identified as High Risk (n=18) had a 
mean of 3.72 (p<0.01) more DTPs than Low Risk patients (n=31).  All but one (94.4%) 
of the High Risk patients had at least one Moderate or Severe DTP, while less than half 
(48.4%) of Low Risk patients had at least one Moderate or Severe DTP.  The majority of 
High Risk patients were eligible for medication reviews in all programs except for 
Newfoundland and Labrador, New Brunswick and Saskatchewan.  Close to a third of 
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Low Risk patients were eligible for medication reviews in Prince Edward Island, Nova 
Scotia and Ontario. 
 
Conclusions:  This screening tool is a trustworthy method for identifying patients in 
community pharmacies who have a large number of DTPs.  Patients identified as High 
Risk using this screening tool may be good targets for community pharmacy based 
comprehensive medication assessments. 
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Chapter One – Introduction 
 
1.1 Overview of the Problem  
 
Many patients in the ambulatory setting suffer from sub-optimal health in part due 
to preventable adverse drug events and poor chronic disease management (CDM).  
Drug related causes account for a significant number of emergency room visits and 
hospitalizations in Canada, a large proportion of which are thought to be 
preventable.(1–3) 
Community pharmacists are in a prime position to address medication 
mismanagement due to frequent contact with patients and specialized training regarding 
medications.  Previous research supports the ability of community pharmacists to 
improve medication management.  For example, significantly improved hypertension(4) 
and dyslipidemia(5)(6) control has been demonstrated when pharmacists performed a 
comprehensive medication assessment within community pharmacies.  Community 
pharmacist-led comprehensive medication assessments have also been shown to 
decrease medication related hospital admission rates in patients with five or more 
medical conditions.(7)  Unfortunately the majority of evidence based interventions 
described in the literature have not been integrated into mainstream community 
pharmacy practice, likely because these studies tested complex and multi-faceted 
interventions that took large amounts of pharmacist time(8), and community 
pharmacists currently spend a limited amount of their time providing such clinical 
services.(9) 
Considering their accessibility and frequent, yet brief, interactions with large 
numbers of patients, community pharmacists may be well suited to screen for patients 
who are at high risk of drug therapy problems (DTPs).  A drug therapy problem is 
defined as  any drug related issue that contributes to sub-optimal patient health 
outcomes.  Examples of DTPs include a drug causing an adverse reaction, a drug at a 
dose too low to achieve the desired therapeutic benefit, and the drug being taken 
incorrectly by the patient.  Many community pharmacists work under very tight time 
constraints and struggle to spend large amounts of time with individual patients, 
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especially on short notice, making a brief screening intervention potentially quite 
feasible.  After identifying patients who are at high risk for DTPs, community 
pharmacists could have the option to manage the high risk patients themselves (if they 
had time and if they were engaging in one of the provincially sponsored medication 
reviews programs) or they could refer the high risk patients to other professionals who 
may be in a better position to provide a comprehensive medication assessment (i.e. 
pharmacists working in primary care teams or outpatient clinics).   
While comprehensive medication assessments have been shown to be valuable, 
it is unclear which patients are best served by this intervention.  This is due to a lack of 
evidence in the literature regarding which patients will benefit the most from a 
pharmacist led comprehensive medication assessment.  The lack of evidence may help 
to explain why the eligibility criteria utilized by all of the provincially funded Canadian 
medication review programs are highly variable and inconsistent.(10)  The identification 
or development of evidence based screening criteria to identify patients at high risk of 
experiencing DTPs would likely assist these provincial programs in creating more 
consistent and effective eligibility criteria, and presumably help pharmacists target the 
most appropriate patients.   
As part of a  systematic literature review of Medline, Embase, International 
Pharmaceutical Abstracts and Google Scholar, as well as a review of the grey literature, 
a screening tool was identified that appeared to have good potential to detect patients 
needing a comprehensive medication assessment and that was thought to be 
reasonable for use in community pharmacies.  The tool was previously tested in an 
outpatient family medicine clinic setting and found to effectively identify patients with 
multiple DTPs (who may benefit from a comprehensive medication assessment)(11); 
however, this screening tool has not been similarly tested in a community pharmacy 
setting.  The tool is comprised of a patient self-administered screening questionnaire 
that includes five short dichotomous questions and it was found to be simple and quick 
to complete by patients who were waiting to see their family physician.(11)  Due to the 
ease of use and the apparent utility of this screening questionnaire within a family 
medicine clinic setting, it was also thought to be potentially useful in community 
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pharmacies for identifying high risk patients with multiple DTPs (who may benefit from a 
comprehensive medication assessment).   
The purpose of this research study was to evaluate the effectiveness of a 
modified version of this screening questionnaire to identify patients at risk for DTPs in a 
community pharmacy setting who may benefit from a medication review. 
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Chapter Two - Literature Review 
2.1 Drug Therapy Problems 
The concept of Pharmaceutical Care (PC) was introduced in 1990 by Hepler and 
Strand.  The goal of PC is “the responsible provision of drug therapy for the purpose of 
achieving definite outcomes that improve the patient’s quality of life”.(12)  These definite 
outcomes are: to cure a disease, eliminate or reduce symptoms of a disease, stop or 
slow the disease, or prevent disease development or symptoms of a disease.  PC may 
only be achieved by the pharmacist interacting and collaborating with other health care 
professionals who are involved in the patient’s care.  Within the therapeutic plan, three 
main goals must be held paramount for the pharmacist: identifying potential or actual 
drug therapy problems, resolving actual drug therapy problems, and preventing drug 
therapy problems.  A drug therapy problem is defined as any drug related issue that 
contributes to sub-optimal patient health outcomes. 
There are seven generally accepted categories of drug therapy problems: 
adverse drug reaction(s) (ADRs), supratherapeutic dose (dose too high), subtherapeutic 
dose (dose too low), inappropriate drug (wrong drug), drug not indicated (taking a drug 
for an unknown reason), drug therapy required (not taking a drug that is necessary for 
optimal treatment) and noncompliance (taking a drug incorrectly).(13)  Management of 
DTPs often requires collaboration between different health care providers; however, 
pharmacists can independently resolve some DTPs.  It is part of the professional 
responsibility of all pharmacists to actively search for and attempt to resolve DTPs. 
 
 
2.2 Patient Morbidity as the Result of Medication Mismanagement  
 Medication mismanagement and drug therapy problems account for a significant 
proportion of hospital admissions and the majority of these may be preventable.(1–3)  A 
Canadian study found that 24.1% of hospitalizations in a large Canadian hospital were 
the result of a drug related issue.(2)  Furthermore, 72.1% of these issues were deemed 
to be preventable.  The vast majority of the identified DTPs that caused hospital 
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admission were serious; 83.8% being of moderate severity, 7.4% being high severity, 
and 0.7% being fatal.  The types of DTPs identified in this study most commonly were 
adverse drug reaction (35.3%), inappropriate drug (17.6%), and noncompliance 
(16.2%). 
In another study, of 1017 patients who visited a Canadian emergency 
department, 122 (12.0%) were deemed to be there due to a medication issue.  Of those 
patients, 68.0% of the issues were likely preventable.(1)  Most commonly, the drug 
related visit was due to an adverse drug reaction or non-compliance.  The authors also 
found that the probability of hospital admission was greater in patients who were visiting 
the emergency department due to a drug related cause, compared to patients visiting 
for any other cause.  Similar research in the United Kingdom found that 6.5% of hospital 
admissions were due to drug related causes, of which 67.2% were deemed 
preventable.(3)   
Clearly this is a major global issue that requires action.  The prevention of drug 
therapy problems is a large role for pharmacists, and comprehensive medication 
assessments may identify DTPs, which may avoid some of these emergency 
department visits and hospitalizations. 
 
2.3 Comprehensive Medication Assessments 
 A comprehensive mediation assessment is a clinical intervention in which a 
health provider (usually a pharmacist) spends dedicated time with a patient, generally in 
a private setting, to review his/her medications and medical conditions, ensuring that the 
patient is receiving optimal treatment for their conditions.  Through comprehensive 
medication assessments (sometimes referred to as Medication Therapy Management, 
or Comprehensive Medication Assessments, or simply Medication Assessments or 
Medication Reviews), the health provider is able to determine if the patient’s drug 
therapy goals are being met and to identify any actual or potential DTPs.  Actively 
searching for DTPs is an important aspect of providing pharmaceutical care.(13) 
 In the IMPACT trial(14), pharmacists were able to identify at least one DTP in 
93.8% of patients who received comprehensive medication assessments.  On average, 
pharmacists in this study identified 4.4 DTPs per patient and the most common 
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problems fell into the following categories: additional medication required (27.0%), non-
compliance (16.5%), sub-therapeutic dose of a drug (16.2%) and adverse drug 
reactions (7.9%). 
 In a large study in the United States, pharmacists were able to identify and 
resolve 5780 DTPs for 2524 patients who received a comprehensive medication 
assessment.(15)  Eighty-nine percent of patient’s therapeutic goals were achieved at 
the final encounter with the pharmacist, an increase of 15% from baseline.   
 Similarly, Roth and colleagues(16) were able to identify a mean of 4.2 DTPs per 
patient in a study where elderly patients in the United Kingdom who were on five or 
more medications received a pharmacist led comprehensive medication assessment.  
Six month follow up found that the majority of the DTPs had been addressed and 
resolved during the study period.  The authors were also able to demonstrate that the 
patients included in the study had a significant reduction in the use of acute health care 
services during the study, potentially due to the resolution of DTPs. 
 Pharmacist led comprehensive medication assessments can clearly identify a 
multitude of potential and actual DTPs in patients, making a potentially significant 
impact on the alarming rates of medication mismanagement in the primary care system. 
However, identifying, resolving and preventing DTPs (by performing comprehensive 
medication assessments) is not currently routine in community pharmacy practice, 
despite the large amount of evidence supporting the benefits of this type of 
pharmaceutical care intervention.   
 
2.4 DTP Identification by Community Pharmacists 
In the community pharmacy setting, the rate of pharmacists identifying DTPs is 
relatively low.  Observational studies indicate that between 0.74% and 2.5% of patients 
visiting community pharmacies are identified as having at least one DTP during routine 
practice.(17–20)  This is much lower than the rates of DTPs found when pharmacists 
practicing in other settings interact with similar patient populations.  In the IMPACT Trial, 
pharmacists practising as co-located members of a family medicine team identified at 
least one DTP in 93.8% of patients.(14)  Pharmacists who systematically reviewed 
repeat prescriptions in a general practice in the United Kingdom were able to identify 
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DTPs in 157 of 285 patients (55.1%).(21)  Another study involving pharmacists 
performing a brief medication review prior to the patient being seen by a physician for 
repeat prescription found that 16.8% of patients had at least one DTP identified, and 
76.8% of these DTPs were then actively managed by the physician.  When no 
medication review was performed, only 8% of patients were identified as suffering from 
at least one DTP, and only 37.5% of the identified DTPs were actively managed by the 
physician during the visit.(22)  Yet another study investigated a short screening 
questionnaire used in community pharmacies, meant to determine if patients familiar to 
the pharmacy were at risk for DTPs.  The results of the questionnaire highlighted that 
even patients well known to the pharmacy had some medication related issues that 
could impact their drug therapy outcomes that the pharmacists were not aware of.(23)  
Based on the literature, it appears that pharmacists practicing in a typical community 
pharmacy setting may be missing large numbers of high-risk patients with DTPs and 
may not be capitalizing on an important opportunity to resolve these DTPs and improve 
patient health.   
Explanations for why  community pharmacists may not be identifying as many 
DTPs as they likely could include: a) There are no evidence based, standardized 
screening procedures in the literature that could be implemented in this setting to assist 
community pharmacists in identifying patients at high risk for DTPs, who may benefit 
from a comprehensive medication assessment.(24)  b) Most community pharmacists 
work under very tight time constraints and do not spend large amounts of time with 
individual patients(9), especially on short notice, making it extremely difficult to perform 
the comprehensive medication assessments that are generally required to effectively 
and thoroughly identify DTPs in individual patients.  
Considering their accessibility and frequent, yet brief, interactions with large 
numbers of patients, many community pharmacists may be well suited to screen for 
patients who are at high risk of drug therapy problems (DTPs).  After identifying patients 
who are at high risk for DTPs, community pharmacists could have the option to manage 
the high risk patients themselves at a later date (if they had time and if they were 
participating in one of the provincially sponsored medication reviews programs) or they 
could refer the high risk patients to other pharmacists who may be in a better position to 
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provide a comprehensive medication assessment (i.e. pharmacists working in primary 
care teams or outpatient clinics).  The identification or development of evidence based 
screening criteria to identify patients at high risk of experiencing DTPs would assist 
community pharmacists who want to test the feasibility and benefits of taking on this 
screening role.  
 
2.5 Refill Encounter as an Opportunity for a Screening Intervention  
A prescription refill encounter at a community pharmacy may be an effective and 
appropriate opportunity for community pharmacists to screen for patients who are at 
high risk of DTPs (if evidence based screening criteria existed).  Processing a new 
prescription usually entails more work for the community pharmacy staff as compared to 
a refill prescription.  In addition to properly dispensing the medication, a new 
prescription must be correctly entered into the pharmacy software and the pharmacist 
must carefully consider the safety and efficacy of the prescribed medication for that 
individual patient, often with more scrutiny than during a prescription refill encounter.  
The initial prescription dispensation is also commonly the time when the pharmacist 
provides the most education to the patient on their new medication, requiring a 
significant amount of the pharmacist’s time.(25,26)  Consequently, it may be most 
feasible and practical for community pharmacists to screen for patients at high risk of 
DTPs during the refill prescription encounter as there may be more time to spend with 
the patient.(27,28) 
 Screening for DTPs during the refill prescription encounter may offer additional 
advantages compared with screening during a new prescription.  The patient may be 
more cognisant regarding their medication(s) and medical condition(s) at a refill, after 
having experienced living with the medical condition(s) and having experience taking 
their medication(s).  In addition, lack of efficacy or the presence of adverse effects can 
only be determined after the patient has been taking the medication.  Likewise, 
adherence problems may only become apparent after a patient experiences the 
medication on a chronic basis.  For these reasons, a prescription refill encounter may 
be an excellent opportunity to screen to DTPs. 
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2.6 Medication Review Programs in Canada 
Most provinces in Canada have implemented government sponsored programs 
to compensate community pharmacies for providing variations of a clinical pharmacist 
service that is commonly referred to as a medication review.  Ontario was the first 
province to remunerate community pharmacies for a standardized medication review 
program in 2007 called MedsCheck.  Since 2007, similar programs have appeared in 
several other provinces.  
Each program has unique expectations regarding the details of the intervention 
and the breadth and depth to which pharmacists are mandated to review and assess 
each patient’s medications.  However, all of these programs share the common goal of 
having a pharmacist meet with a patient to provide education about the medications 
they are taking; to provide the patient (and pharmacy) with a current best possible 
medication history; to identify, and address DTPs; and to elucidate and monitor patients’ 
progress towards the goals of their drug therapy.   
The provincial funding available for these programs is limited and pharmacist 
time continues to be at a premium.  Consequently, each province has limited patient 
access to these services by developing strict eligibility criteria.  The presumed goal of 
the eligibility criteria is to ensure that these programs improve patient outcomes and 
utilize public resources responsibly, by providing the service to the highest risk patients 
who will likely benefit the most.   
Eight of the ten provinces in Canada have a provincially funded program that 
could be considered a medication review for individuals who are members of the 
respective provincial drug plans, although not all use the term ‘medication review’ to 
describe the service being provided. Table 1 contains an overview of the eligibility 
requirements of these provincial programs.  Manitoba, Quebec and the territories did 
not offer provincially funded medication review program similar to the other provinces, 
and are therefore not included in the table.  Some provinces offered more than one 
variation of the service, which is reflected in Table 1.(10)  
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Table 1: Overview of Eligibility Requirements for Community Pharmacy Medication Review Programs in Canada(10) 
Province Name of 
Program 
Eligibility Requirements 
Newfoundland 
and Labrador 
(NL) 
 
Medication 
Review(29) 
Individuals with diabetes taking an oral hypoglycemic agent and/or insulin. 
Prince Edward 
Island (PEI)  
 
PEI Basic 
Medication 
Review(30)(31)  
Individuals taking 3 or more chronic medications covered by PEI Pharmacare 
programs, and are participants in one of the following PEI provincial programs: 
Seniors’ Drug Cost Assistance, Financial Assistance, or Private Nursing Home.   
Prince Edward 
Island (PEI) 
PEI Diabetes 
Medication 
Review(30)(31) 
Individuals enrolled with the PEI Pharmacare Diabetes program and on at least 1 
medication covered by PEI Pharmacare programs used in the treatment of 
diabetes. 
Nova Scotia 
(NS) 
Basic Medication 
Review 
Service(32) 
 
Beneficiaries of any NS Pharmacare program (except the Under 65 – Long Term 
Care Program) who do not reside in a nursing home, home for special care, and 
do not receive medication in compliance packaging.  Individuals must be taking 3 
or more prescription medications that are used for the treatment of chronic 
conditions, and are covered by the NS Pharmacare program. 
Nova Scotia 
(NS) 
Advanced 
Medication Review 
Service(32) 
Beneficiaries of the Seniors’ Pharmacare Program who do not reside in a nursing 
home, home for special care and do not receive medication in compliance 
packaging.  Individuals must be taking 4 or more prescription medications, or be 
taking one of the designated medicationsa. 
Individuals must have at least one of the designated diseasesb. 
New Brunswick 
(NB) 
PharmaCheck(33) NB Prescription Drug Program plan A (Seniors) beneficiary taking 3 or more 
chronic prescription medications. 
Ontario (ON) MedsCheck(34) Individuals must be on a minimum of 3 prescription medications for chronic 
condition(s). 
Ontario (ON) MedsCheck for 
Ontarians living 
with Diabetes(35) 
Individuals must be diagnosed with Type 1 or Type 2 diabetes, and be taking one 
or more medications for treating diabetes. 
Ontario (ON) MedsCheck at 
Home(36) 
Individuals must be on a minimum of 3 prescription medications for chronic 
condition(s) and are not able to attend to the community pharmacy. 
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Ontario (ON) MedsCheck for 
Long Term Home 
Care 
Residents(37) 
Individuals must reside in a licensed Long-Term Care Home. 
Saskatchewan 
(SK) 
Compliance 
Packaging with 
Medication 
Assessment(38) 
Individuals must be eligible Home Care patients or Mental Health patients, with a 
minimum of one medication covered by the SK Drug Plan in the compliance 
package.   
Saskatchewan 
(SK) 
Saskatchewan 
Medication 
Assessment 
Program(39) 
Individuals age 65 and over, living in the community, and: (1) be taking 5 or more 
chronic medications, of which 3 must appear on PIP (the provincial database of 
dispensed medication); or, (2) be taking an anticoagulant medication; or, (3) be 
taking a medication on the Beers List.  
Alberta (AB) Comprehensive 
Annual Care Plans 
for Albertans(40) 
Individuals with “complex needs”c. 
Alberta (AB) Standard 
Medication 
Management 
Assessment for 
Albertans(40) 
Individuals must have at least 1 “chronic condition”c, and be taking at least 3 
different prescription medications or 2 prescription medications and insulin. 
British 
Columbia (BC) 
Medication Review 
Services (41) 
Individuals must have at least 5 qualifying medications (discreet DINs) active 
within the last 6 months on the provincial PharmaNet system, and there must be a 
clinical needd. 
a) Designated medications include methyldopa, indomethacin, cyclobenzaprine, diazepam, chlordiazepoxide, clorazepate or amitriptyline. 
b) Designated diseases include asthma, diabetes, hypertension, hyperlipidemia, congestive heart failure, chronic obstructive pulmonary disease or arthritis. 
c) ”Complex needs” defined as the presence of both chronic condition(s) and risk factors.  There are two categories of patients with “complex needs”; those with at least two chronic 
conditions and those with one chronic condition and one or more risk factor.  Chronic conditions include: hypertensive disease, diabetes mellitus, chronic obstructive pulmonary 
disease, asthma, heart failure, ischaemic heart disease, and mental health disorder.  Risk factors include: tobacco use, obesity, and addictions. 
d) Clinical need is obtained when a prescriber requests a medication review, when the patient has multiple diseases, the patient has chronic diseases, the patient’s medication regimen 
includes one or more non-prescription medications, the patient’s medication regimen includes one or more natural health products, then patient has a drug therapy problem(s), the 
patient was recently discharged from hospital, the patient has multiple prescribers, and the patient is receiving medication(s) that require laboratory monitoring 
13
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The most striking aspect of these medication review programs is the lack of 
consistency with respect to the eligibility criteria utilized by each provincial program.  
Despite providing similar clinical pharmacist interventions, there appears to be little 
congruence amongst programs regarding the patients who are eligible to receive the 
services.  Some programs require patients to be taking a minimum number of chronic 
medications to be eligible (but no consistent number of medications is used), while other 
programs are available to patients taking certain high-risk medications (e.g., 
anticoagulants) or with specific chronic diseases (e.g., diabetes), regardless of the 
number of medications taken.  Some use a combination of these approaches, where 
eligible patients must suffer from a specific chronic disease and be taking a minimum 
number or type of medications.   
The prevailing similarity amongst these programs’ eligibility criteria is that most 
appear to be based on known risk factors for preventable medication related ADRs or 
the presence of DTPs.  There are many agreed upon risk factors for ADRs and DTPs 
including, but not limited to; advanced age, certain medical conditions, high number of 
medications or medication doses per day, narrow therapeutic index drugs and large 
number of comorbidities.(42–44)  Unfortunately the evidence supporting these risk 
factors does not provide clear thresholds for people who are “High Risk” or “Low Risk”, 
making it very difficult to use these risk factors to create appropriate eligibility criteria for 
medication review programs.   
The eligibility criteria utilized by these provincially funded medication review 
programs in Canada are inconsistent and highly variable, raising doubt that all programs 
are targeting the most appropriate patients for these new services.  The development of 
an evidence based tool or screening protocol that is capable of identifying patients who 
will benefit from a community pharmacist medication review would allow provincially 
funded medication review programs to adopt consistent eligibility criteria that would 
ensure health care resources are used responsibly and patient outcomes are improved 
optimally. 
 
 
13 
 
2.7 Lack of an Evidence-based Screening Protocol for Patients at High 
Risk for DTPs in the Community Pharmacy 
Very little research has been published describing systematic screening for 
patients at high risk for DTPs in the community pharmacy setting, and the majority of 
the screening methods in the literature are in the form of time-intensive structured 
interviews, which may be difficult to implement in a typical community pharmacy.   
Hugtenburg and colleagues employed a pharmacist-led interview asking patients 
to describe their experience with their medications when they received their first refill of 
a new prescription (i.e. the second prescription), to screen patients who might be 
experiencing DTPs in The Netherlands.(45)  In this study, 22.3% of patients who were 
screened using the interview tool were identified as experiencing at least one DTP.  The 
control pharmacy did not engage patients in the interview, and identified zero patients at 
risk of DTPs.  However, the pharmacist-led interviews had poor uptake, and staff 
required multiple re-education sessions to ensure proper handling of the second 
prescriptions. 
A computer generated process to screen for patients at risk for DTPs based on 
patient’s overall drug costs was evaluated in Switzerland.(19)  The program selected 
patients whose six month drug cost exceeded $1440 United States Dollars (USD).  
These patient’s records were then evaluated by community pharmacists, who found that 
the screened patients experienced an average of 2.6 DTPs per patient.  Unfortunately, 
the authors of this uncontrolled study did not validate the screening process by 
confirming the presence of the DTPs with each patient; they simply identified potential 
DTPs by reviewing the patient’s medication lists.  This type of screening would not be 
effective for patients who were patrons of multiple pharmacies, and would also not 
include patients’ over the counter medications and natural health products. 
Gordon and colleagues used a semi-structured pharmacist-led interview to 
screen for patients at risk for DTPs.  A series of open and closed ended questions were 
asked in a community pharmacy and clinic setting to adult patients on cardiovascular 
medication for a cardiovascular condition.(46)  The patient participation rate in the 
pharmacy was high, as 69.7% of those who were approached agreed to the screening 
interview.  Greater than one third of the individuals screened using this process were 
14 
 
identified as having at least one DTP.  While the interview was effective at screening 
patients who ultimately experienced DTPs, each screening interview took a median time 
of 12 minutes, which may be too great of a time burden on the majority of community 
pharmacies to simply screen for patients who may benefit from a subsequent 
medication assessment.  
In a European study, a standardized questionnaire was used by pharmacists to 
screen for patients at risk for DTPs in people who presented at the community 
pharmacy with hospital discharge prescriptions.(47)  The study concluded that patients 
who were determined to be at risk of DTPs using the questionnaire had an average of 
1.6 DTPs each.  This questionnaire targeted patients post hospital discharge, and it is 
not known if this questionnaire would be effective at screening for DTPs in the general 
population. 
In another study, researchers asked patients who were over 65 years of age and 
on at least two chronic medications to complete a ten question self-assessment 
questionnaire to screen for people at high risk of DTPs.(48)  This study was performed 
in the United States, at three community pharmacies in one large city.  The author 
assessed patient acceptability of the questionnaire, the reliability and validity of the 10 
individual questions, and how the questions correlated with subsequent Drug Regimen 
Review (DRR) severity scores, which is an indication of DTP risk. However, they did not 
perform comprehensive medication assessments on the individual patients who 
completed the questionnaire to confirm the presence of DTPs.  All patients were able to 
complete the questionnaire without assistance, patient acceptability was high, and 
patients had high levels of confidence in their ability to remember their prescription and 
non-prescription medications.  Patients were able to correctly answer the questions the 
majority of the time, and five of the ten questions were significantly correlated with an 
increased DRR score.(11)  
A 59 item questionnaire (named “The DTP Risk Assessment Tool”) was recently 
developed for use by home care nurses who care for elderly patients.(49)  The 
questionnaire includes sections about medication use, home life as well as current or 
recent symptomology.  The questionnaire is intended to be used as a referral guide, and 
includes a section where a nurse can recommend one of many action plans.  The “DTP 
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Risk Assessment Tool” has not yet been validated with patients, and therefore its 
effectiveness has not been determined.  The length of the questionnaire may also not 
be conducive to being used in community pharmacies. 
The previously described interventions and screening tools have varying levels of 
usefulness in identifying patients who are at high risk for or who are suffering from 
DTPs; however, none of the interventions have been integrated into mainstream 
community pharmacy practice.  There are several barriers to the uptake of these 
screening protocols.  Screening pharmacy records based on medication cost(19) to 
identify patients at high risk of DTPs is unreliable as it misses non-prescription products 
and does not allow for patient interaction.  Pharmacist-patient interviews that were 
utilized in the reviewed studies were very time consuming and required a private space 
to complete, which can make them difficult to implement within a typical community 
pharmacy.(46)  The key to a feasible screening process that has the potential to be 
useful for community pharmacists and their patients may lie in the process being simple 
and requiring a minimal time commitment from the pharmacy staff.   
 
2.8 The Langford Screening Questionnaire 
Only one screening tool was identified in the literature that had potential for 
mainstream use in a community pharmacy setting (which was not previously discussed 
in Chapter 2.7).  The Langford Screening questionnaire is composed of five questions 
with dichotomous “Yes” or “No” answers (See Appendix 4).(11)  The questions are 
based on known risk factors for the presence of DTPs and have previously been 
determined to have high patient acceptability and patient/investigator reliability.(44,48)  
The risk factors included in the questionnaire are: taking five or more medications, 
taking 12 or more doses of medication daily, taking medication that requires frequent 
therapeutic drug monitoring, and being treated for three or more different medical 
conditions.  
In the Langford study, patients taking two or more medications were approached 
in the waiting room of a large family physician’s clinic and asked to self-administer the 
five item questionnaire.  The 194 patients who completed the questionnaire were 
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randomized to either a control group (89 patients; standard screening process in which 
the questionnaire responses were ignored and patients were referred to a pharmacist 
for a comprehensive medication assessment only if the physician felt a referral was 
necessary) or the intervention group (105 patients; patients referred to a pharmacist for 
a comprehensive medication assessment if they responded “Yes” to three or more 
questions on the questionnaire).  All patients referred to the pharmacist in both groups 
received a comprehensive medication assessment.  The study found that pharmacists 
identified a similar number of DTPs in both patient groups, regardless of the source of 
the referral (intervention group 3.1 DTPs per patient, standard screening process 2.4 
DTPs per patient).  However, the screening questionnaire identified a much larger 
number of high risk patients.  A total of 20.0% (n=21) of the patients from the 
intervention group were screened as being high risk and were referred to a pharmacist, 
compared with 5.6% (n=5) of the patients in the control group (p=0.003).  This suggests 
that although standard physician screening is effective at identifying high risk patients, 
the screening questionnaire was able to identify more high risk patients.  The authors 
concluded that the screening questionnaire was a useful method to identify patients at 
high risk of DTPs when compared to physician referrals, and could be used, in addition 
to standard physician referrals within a family medicine clinic setting, to increase the 
number of patients at high risk of DTPs being referred to pharmacists for a 
comprehensive medication assessment.(11) 
Although the screening questionnaire was tested in a family physician office 
setting, it is possible that it may also be effective in a community pharmacy setting.  The 
screening questionnaire is self-administered, which requires very little time from the 
pharmacist, and patients have previously demonstrated that no assistance is typically 
required to answer the questions.(48)  Scoring the responses and segregating patients 
into High Risk and Low Risk groups is quick and simple due to the dichotomous nature 
of the questionnaire.  For these reasons, the Langford screening questionnaire may be 
an excellent tool for screening for patients at high risk for DTPs in the community 
pharmacy setting. 
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Chapter Three - Study Purpose 
The purpose of this research study was to evaluate the effectiveness of using a 
modified Langford screening questionnaire (renamed the Medication Risk Assessment 
Questionnaire) to identify patients at risk for drug therapy problems in a community 
pharmacy setting who may benefit from a comprehensive medication assessment.   
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Chapter Four – Research Objectives 
1.  To determine if the Medication Risk Assessment Questionnaire identifies patients 
within a community pharmacy setting who have a significant number of DTPs. 
a. To determine if patients who screen High Risk by the Medication Risk 
Assessment Questionnaire have more drug therapy problems than those 
who screen Low Risk. 
i. Hypothesis: Patients who screen High Risk will have on average 2 
more drug therapy problems than patients who screen Low Risk. 
b. To determine if patients who screen High Risk with the Medication Risk 
Assessment Questionnaire have proportionally more serious or potentially 
more dangerous drug therapy problems than those who screen Low Risk. 
 
2.  To establish the level of agreement between the patient self-administered responses 
to the Medication Risk Assessment Questionnaire, and the subsequent risk 
categorization with the correct responses and categorization as determined after 
completion of a comprehensive medication assessment with a pharmacist. 
i. Hypothesis: The strength of the agreement will be “Very Good” or “Excellent” (k 
= 0.81 – 1.0) 
 
3.  To compare the Medication Risk Assessment Questionnaire with the eligibility 
requirements of provincial medication review programs in Canada. 
a. To determine the proportion of patients who screen High Risk with the 
Medication Risk Assessment Questionnaire who would be eligible for a 
medication review under each of the provincial medication review 
programs in Canada. 
b. To determine the proportion of patients who screen Low Risk with the 
Medication Risk Assessment Questionnaire who would be eligible for a 
medication review under each of the provincial medication review 
programs in Canada. 
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Chapter Five –Methods and Procedures 
 All protocols were approved by the University of Saskatchewan’s Behavioural 
Research Ethics Board (Certificate of Approval: BEH 13-293) prior to the 
commencement of this study.  All personal data, including medical and health 
information, which was collected during this research has been managed in accordance 
with all HIPA and PIPEDA guidelines. 
 
5.1 Modification of the Langford Screening Questionnaire  
The chosen screening questionnaire was identified from a previous publication 
by Langford et al. (2006), in which the questionnaire was tested in a family medicine 
clinic setting (see Chapter 2.8).  The questionnaire was pilot tested on five individuals 
(three pharmacists and two laypersons) prior to use in the study to ensure the questions 
were clear and understandable.  Two of the five individuals felt that the term “non-
prescription products” from Question #1 (Do you take 5 or more medications?), was 
unclear, and did not include vitamins, minerals or herbal products.  Based on the pilot 
test, it was decided that the question should be changed to explicitly include vitamins 
and herbals by adding the phrase “including prescription and non-prescription products, 
vitamins and herbals).  No other issues were identified during pilot testing. 
The medications in Question #5 (Do you take any of the following medications?) 
were updated to reflect modern prescribing practices and recent evidence regarding 
medications that are implicated in high numbers of adverse drug reactions.  Drugs that 
were no longer commonly prescribed in ambulatory settings (quinidine, phenobarbital, 
procainamide and theophylline)(50) were removed from the list.  Drugs added to the list 
included non-steroidal anti-inflammatory drugs (NSAIDs), opioids, insulin, rivaroxaban, 
dabigatran and apixaban.  NSAIDs and opioids are classified as analgesics by Health 
Canada, and were among the top 10 drug groups of most common suspects for 
adverse drug reactions reported to the Canada Vigilance Program, which monitors 
adverse drug reporting.(51)  Similarly, rivaroxaban, dabigatran and apixaban are 
classified as antithrombotic agents, which were number seven in these top 10 drug 
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groups.  The Institute for Safe Medication Practice (ISMP) define insulin and opioids as 
“high alert” medications because they have an increased risk of causing significant 
harm when used inappropriately, and may require supplemental action to reduce the 
risk of inappropriate use.   
Each drug, or class of drugs, that is now listed in the updated Question #5, with 
the exception of phenytoin, appears on at least one of the three following lists: ISMP’s 
List of High-Alert Medications in Community/Ambulatory Healthcare(52), Canada 
Vigilance Program’s top 10 groups of suspect health products most commonly reported 
in 2012(53), and the Beers criteria for Potentially Inappropriate Medication Use in Older 
Adults.(54)  See Table 2.  For the purposes of this document, the modified version of 
the Langford Questionnaire is referred to as the “Medication Risk Assessment 
Questionnaire”. 
 
Table 2.  Drugs included in Question #5 of the Medication Risk Assessment 
Questionnaire and presence of each drug (or class of drugs) on three medication alert 
lists. 
Drug/Class of Drugs ISMP High Alert Canada Vigilance 
Top 10 
Beers Criteria 
Carbamazepine Yes No No 
Lithium No Yes No 
Phenytoin No No No 
Digoxin No No Yes 
Insulin Yes No No 
Drugs for pain (opioids 
and NSAIDs) Yes Yes Yes 
Drugs for preventing 
blood clots (warfarin, 
dabigatran, 
rivaroxaban, apixaban, 
ASA) 
Yes Yes Yes (Dabigatran and ASA) 
Sulfonylureas (drugs 
to lower blood sugar) Yes No Yes 
Methotrexate Yes Yes No 
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5.2 Research Setting 
Three different community pharmacies in Saskatoon were approached to act as 
the setting for patient recruitment for this research project.  Three pharmacies were 
recruited to increase the generalizability of the results (compared to recruiting just a 
single pharmacy).  Pharmacies that were recruited were: (a) those that did not have a 
focus on specialty practice, such as compounding pharmacies, or methadone 
pharmacies; (b) those with the availability of a private consultation area for 
comprehensive medication assessments to be performed and; (c) those with daily 
average prescription volumes between 75 and 400.  This prescription volume was 
chosen to ensure that the pharmacies would have adequate patient populations to 
increase the probability of recruiting an appropriate number of patients. 
Pharmacies were invited to participate by phone and the researcher discussed 
the project and protocol with invited dispensary staff in person to ensure they had a 
thorough understanding of what was required of them before they were accepted as a 
study site.  Random selection of pharmacies was considered, however; due to the 
somewhat restrictive pharmacy inclusion criteria, and requiring the community 
pharmacy staff to collaborate with the researcher during the comprehensive medication 
assessment recommendations and accept responsibility for the patient once the 
researcher’s time was complete at the site, it was decided to approach specific 
pharmacies that (based on the research team’s previous experiences) may have a high 
likelihood of successfully participating.  Community pharmacy staff was also required to 
occasionally aid in patient information gathering by requesting lab results from 
physicians, as well as provide therapeutic recommendations to the prescriber.   
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5.3 Experiment One: To establish the level of agreement between the 
patient self-administered responses to the Medication Risk Assessment 
Questionnaire, and the subsequent risk categorization with the correct 
responses and categorization as determined after completion of a 
comprehensive medication assessment with a pharmacist 
  
5.3.1 Study Procedure – Data Collection 
1) Patients who met the inclusion criteria (see below) were flagged by the regular 
community pharmacy dispensary staff during normal prescription processing.  
Potentially eligible patients were then approached in consecutive order (the order 
in which they requested their refill prescription) by the researcher at the 
pharmacy counter, who explained the purpose of the research project and 
attempted to obtain informed consent from the patient.  The number of people 
approached and the number of people who consented was recorded. 
a. Inclusion criteria: 
i. Adult patients (equal to or greater than 18 years old) who were 
physically present in the pharmacy and requesting a refill 
prescription (as defined below) for themselves. 
ii. Patients who could speak and read English and who were capable 
of completing the Medication Risk Assessment Questionnaire 
themselves (agents of the patient were not permitted to complete 
the Medication Risk Assessment Questionnaire on behalf of the 
patient). 
iii. Patients must be picking up at least one refill prescription, which 
was defined as: a prescription medication that is the same drug at 
the same dose and regimen (i.e. directions for administration) as 
the previous dispensation.  The previous dispensation must have 
occurred within the previous 6 months. 
b. Exclusion criteria 
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i. Patients who were unable to read and write in English. 
ii. Patients with a lack of competence to self-administer the 
Medication Risk Assessment Questionnaire (e.g., severe dementia) 
were excluded from the study. 
iii. Patients known to the dispensary staff that may be unfit for the 
study due to a variety of factors such as potential for patient 
agitation or patient time constraints.  Patients not deemed 
appropriate for the study by the dispensary staff were not 
approached to participate in the study.   
2) Patients were offered a token of appreciation for participating in the research if 
they consented and completed participation in the study ($10 gift card). 
3) Patients who provided informed consent were asked to complete the Medication 
Risk Assessment Questionnaire (See Appendix 1), as well as a patient 
demographics form (See Appendix 2) and handed the forms back to the 
researcher in a sealed envelope.  The patient’s name was written on the 
Medication Risk Assessment Questionnaire so that the responses could be 
analyzed later.  The sealed envelopes were not opened until all assessments 
and patient data collection were complete. 
4) All patients who completed the Medication Risk Assessment Questionnaire and 
demographics form were asked to participate in a comprehensive medication 
assessment with the researcher.  The comprehensive medication assessments 
were all performed by the researcher (RP) and they were scheduled to take 
place in the community pharmacy’s private counseling room at a date that was 
mutually convenient to the participant and the researcher.   
5) The process for the performing the comprehensive medication assessments was: 
a. Gather patient medical history. 
b. Gather information to complete a Best Possible Medication History 
(BPMH), including all medications (prescription and non-prescription 
products), doses and regimens using a standardized form (Appendix 3). 
c. Assess patient for presence of DTPs. 
d. Request lab work from the patient’s physician(s) if required. 
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e. Compose consultation letter to the patient’s most responsible physician 
based on the comprehensive medication assessment, including detailed 
recommendations for management of any identified DTPs. 
f. Forward a copy of the consultation letter to the patient’s community 
pharmacy for completeness of the patient’s record. 
6) Patients who completed the Medication Risk Assessment Questionnaire were 
categorized into two groups at the completion of the study, after the 
comprehensive medication assessment was completed.  These thresholds for 
defining risk groups are the same thresholds used in the original evaluation of the 
Medication Risk Assessment Questionnaire.(11,48) 
a. Those that responded “Yes” to less than three questions were categorized 
to the Low Risk group. 
b. Those that responded “Yes” to three or more questions were categorized 
to the High Risk group. 
5.3.2 Study Procedure – Data Analysis 
 
 After the comprehensive medication assessment was complete, the researcher 
used the data collected during the assessment process to determine if the patient self-
administered Medication Risk Assessment Questionnaire was completed accurately by 
determining the level of agreement between the self-administered Medication Risk 
Assessment Questionnaire responses (and subsequent risk categorization) and the 
correct responses (and risk categorization) based on information collected during the 
comprehensive medication assessment, to determine if patients were able to correctly 
answer each question (and be assigned to the correct risk categorization).  All data was 
entered and analyzed in IBM SPSS version 22.0. 
Demographic and clinical characteristics of the patients were presented 
descriptively.  The Kappa value describes the statistical level of agreement for 
categorical variables(55).  Table 3 shows common Kappa Values and the 
corresponding levels of agreement.   
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Table 3.  Level of agreement as described by Kappa value(55) 
Kappa Value Level of Agreement 
<0 None 
0.01-0.20 Poor 
0.21-0.40 Slight 
0.41-0.60 Fair 
0.61-0.80 Good 
0.81-0.92 Very Good 
0.93-1.00 Excellent 
 
1) The Kappa coefficient of agreement was calculated separately for each of the 
five questions in the Medication Risk Assessment Questionnaire.  The number of 
observed agreements, Kappa coefficient as well as the level of agreement is 
reported. 
2) The number of patients who screened High Risk based on the self-administered 
Medication Risk Assessment Questionnaire results was compared to the number 
of patients who screened High Risk based on the responses (and risk 
categorization) from information collected during the comprehensive medication 
assessment to determine the ability of the Medication Risk Assessment 
Questionnaire to accurately place patients into the High Risk category when it is 
self-administered by patients. 
a. The Kappa coefficient of agreement was calculated and reported, along 
with the number of observed agreements and the level of agreement. 
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5.4 Experiment Two: To determine if the Medication Risk Assessment 
Questionnaire identifies patients within a community pharmacy setting who 
have a significant number of DTPs 
5.4.1 Study Procedure – Data Collection 
 Data for Experiment Two was collected during the data collection procedure of 
Experiment One.   
1) DTPs identified during the comprehensive medication assessments with the 
patients were documented as part of the standard patient care process.   
a. By reviewing the information and records from the comprehensive 
medication assessment (including pertinent lab values, when required), 
DTPs were identified, counted and recorded for each patient.   
b. Each DTP was classified into one of the following eight DTP categories 
based on the characteristics of the DTP. 
i. Adverse drug reaction 
ii. Supratherapeutic dose 
iii. Subtherapeutic dose 
iv. Inappropriate drug 
v. Drug not indicated 
vi. Drug therapy required 
vii. Noncompliance 
viii. Unsure or Other DTP 
5.4.2 Study Procedure – Data Analysis 
All data was entered and analyzed in IBM SPSS version 22.0. 
1) The number of DTPs identified in the High Risk group and the Low Risk group 
were compared. 
a. The mean number of DTPs per patient was calculated for the High 
Risk and Low Risk groups. 
b. A Mann-Whitney U-test was used to compare the mean number of 
DTPs per patient between the High Risk and the Low Risk groups and 
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to determine if the difference was statistically significant.  The Mann-
Whitney U test was selected as the data was non-parametric.  
2) Descriptive statistics were used to report the number of DTPs which belong to 
each DTP category for both High Risk and Low Risk groups. 
3) The severity of all DTPs was determined and analyzed. 
a. DTP severity was determined by the researcher based on the adapted 
Schneider criteria(56) as described in Appendix 5.  DTPs were 
stratified into Mild, Moderate or Severe categories based on the 
criteria.  This severity index was chosen, as it was the best objective 
measure for assigning severity scores to DTPs for community dwelling 
patients that was identified in the literature.  The researcher had 
access to all patient related documents that were available to the 
pharmacist during the comprehensive medication assessments (and 
the documentation created by the pharmacist) to assist in the risk 
stratification process (including description of identified DTPs, 
pharmacist consult letters, medication lists, medical history, laboratory 
values, etc.) 
b. DTP severity scores initially assigned by the researcher were agreed 
upon with two external auditors (one pharmacist and one physician). 
i. Each of the external auditors were given all patient related 
documents that were available to the pharmacist during the 
medication reviews (and the documentation created by the 
pharmacist) to assist in the risk stratification process (including 
description of identified DTPs, pharmacist consult letters, 
medication lists, medical history, laboratory values, etc.).  Each 
auditor independently assigned a risk category to each identified 
DTP (using the adapted Schneider criteria), without knowing the 
risk score that was initially assigned by the researcher.  The 
researcher then compared the two auditor’s risk scores with his 
own previously assigned risk score.  In each case where all 
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three did not agree on the risk score, the DTP was flagged for 
subsequent discussion and review.    
ii. Each flagged DTP in which all three reviewers did not agree 
regarding the risk score was discussed with the two auditors 
and the researcher, and a severity score was agreed upon by all 
three individuals.  The unanimously agreed upon severity was 
recorded as the approved final severity score for that DTP. 
c. Pearson Chi squared analysis was performed to compare the number 
of patients in each group who had at least one Moderate or Severe 
DTP. 
d. A Mann-Whitney U was used to compare the mean number of 
Moderate or Severe DTPs in the High Risk and the Low Risk groups. 
 
5.5 Experiment Three: To compare the Medication Risk Assessment 
Questionnaire with the eligibility requirements of provincial medication 
review programs in Canada 
 
5.5.1 Study Procedure – Data collection  
 Data for Experiment Three was collected during the data collection procedure of 
Experiment One.   
1) Individuals who identified as High Risk based on their self-administered 
Medication Risk Assessment Questionnaire answers had information from the 
comprehensive medication assessment reviewed to determine if they would 
qualify for any of the following provincially funded medication review programs 
(see Table1 for a full description of the eligibility criteria of each program).   
a. Newfoundland and Labrador Medication Review 
b. Prince Edward Island Basic Medication Review or Prince Edward Island 
Diabetes Medication Review 
c. Nova Scotia Basic Medication Review Service or Nova Scotia Advanced 
Medication Review Service 
29 
 
d. New Brunswick PharmaCheck 
e. Ontario MedsCheck, MedsCheck for Ontarians living with Diabetes, 
Ontario MedsCheck at Home or Ontario MedsCheck for Long Term Care 
Home Residents 
f. Saskatchewan Compliance Packaging with Medication Assessment or 
Saskatchewan Medication Assessment Program 
g. Comprehensive Annual Care Plans for Albertans or Standard Medication 
Management Assessment for Albertans 
h. British Columbia Medication Review Services 
2) Individuals who identified as Low Risk based on their self-administered 
Medication Risk Assessment Questionnaire answers had information from the 
comprehensive medication assessment reviewed to determine if they would 
qualify for any of the following provincially funded medication review programs  
a. Newfoundland and Labrador Medication Review 
b. Prince Edward Island Basic Medication Review or Prince Edward Island 
Diabetes Medication Review 
c. Nova Scotia Basic Medication Review Service or Nova Scotia Advanced 
Medication Review Service 
d. New Brunswick PharmaCheck 
e. Ontario MedsCheck, MedsCheck for Ontarians living with Diabetes, 
Ontario MedsCheck at Home or Ontario MedsCheck for Long Term Care 
Home Residents 
f. Saskatchewan Compliance Packaging with Medication Assessment or 
Saskatchewan Medication Assessment Program 
g. Comprehensive Annual Care Plans for Albertans or Standard Medication 
Management Assessment for Albertans 
h. British Columbia Medication Review Services 
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5.5.2 Study Procedure – Data Analysis  
All data was entered and analyzed in IBM SPSS version 22.0. 
1) Patients who screened High Risk with the Medication Risk Assessment 
Questionnaire who qualified for each program were analyzed using descriptive 
statistics.  
2) Patients who screened Low Risk with the Medication Risk Assessment 
Questionnaire who qualified for each program were analyzed using descriptive 
statistics.  
 
5.6 Sample Size Calculation 
The sample size calculation was performed presuming that both the High Risk 
and Low Risk groups would be similar in size.  A difference of two or more in the mean 
number of DTPs between High and Low Risk groups was hypothesized to be a clinically 
significant difference.  Clinical significance is a subjective measure, based on the 
judgement of the professional.  For this study, clinical significance is related to the 
amount of harm reduced (such as reduction in the potential rate or severity of adverse 
drug reactions, and decreased number of negative health events such as myocardial 
infarction), the potential for years of life saved and the quality of life years gained.  With 
a mean difference of two DTPs between the High Risk and Low Risk groups, the 
likelihood of identifying at least one clinically important DTP (i.e. one that when 
resolved, would amount to a reduction in harm) was thought to be high. 
  Based on that hypothesis, the power calculation was computed as follows: 
𝑛 = 2
𝑑2
× 𝑐0.05,80% 
Where n is equal to the number of participants required in each group, d is equal to the 
standardized difference, and c is a constant for 0.05 α, 80% β.(57) 
The standardized difference is equal to the target difference divided by the 
standard deviation.  Due to a lack of existing research data in the literature review 
regarding this population and these endpoints, the standard deviation of the number of 
drug therapy problems in this population was an estimate based on previous experience 
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and clinical judgement.  Varying the estimates of the standard deviation resulted in a 
variety of sample sizes. See Table 4. 
 
Table 4.  Estimates of sample size required for study 
Standard Deviation estimate  Standardized 
difference (d) 
Sample size per group (n) 
0.8 2.5 3 
1.2 1.666 6 
1.8 1.111 13 
2.2 0.9091 19 
3 0.6666 36 
 
This table demonstrates that even with an expected large standard deviation in 
the number of DTPs in the population, a sample size of less than 100 total patients was 
needed to be recruited for this study.  This number was thought to be attainable during 
the 12 week data collection period that was thought to be manageable for a Master of 
Science project. 
 
 
5.7 Researcher’s Role 
 
In this study, the researcher had many roles.  The researcher was a licensed 
pharmacist, and was the pharmacist that was directly involved in patient care (i.e., 
performing all of the comprehensive medication assessments with patients who 
consented to participate in the study).  The researcher was also responsible for 
approaching potential participants in the pharmacies, as well as obtaining consent from 
patients and providing the Medication Risk Assessment Questionnaire to patients.  The 
researcher also performed all data analyses. 
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Chapter Six – Results 
6.1 Patient Recruitment 
Three pharmacies were recruited to participate as study sites for this project.  
Each pharmacy was located in a different neighbourhood on the east side of the City of 
Saskatoon: Shoppers Drug Mart at Broadway and Taylor, Pharmacy First on 8th Street 
and Safeway Pharmacy in University Heights.  Population statistics from the 
neighbourhoods surrounding each pharmacy was obtained from the 2011 City of 
Saskatoon Neighbourhood Profile to provide additional information (beyond what was 
collected from each individual participant during the study) about the population in which 
this study was performed.(58) 
Shoppers Drug Mart at Broadway and Taylor in Saskatoon is surrounded by the 
Adelaide-Churchill, Avalon, Buena Vista, Haultain and Queen Elizabeth 
neighbourhoods.  Pharmacy First on 8th Street borders Greystone, Brevoort Park, 
College Park, College Park East and Wildwood .  Safeway Pharmacy in University 
Heights serves the areas of University Heights, Forest Grove, Arbor Creek, Willowgrove 
and Erindale.  Information regarding the communities that surround the three 
pharmacies is presented in Table 5.  While many patients frequent pharmacies that are 
in their neighbourhoods, patients also choose pharmacies based on other factors such 
as convenience, loyalty programs and price(59); therefore, not all patients recruited in 
each pharmacy necessarily lived in the surrounding neighbourhoods. 
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Table 5.  Pharmacy neighbourhood demographics 
 Shoppers Drug 
Mart Broadway 
and Taylor 
Neighbourhood 
Pharmacy First 
on 8th Street 
Neighbourhood 
Safeway 
Pharmacy 
University 
Heights 
Neighbourhood 
Population 15387 23779 21149 
Average Annual 
Household Income $69 996 $71 994 $106 267 
English as First Language 
(%) 87.9 76.2 85.9 
No Education 
Certificate/Diploma/Degree 
(%) 
12.0 11.5 10.4 
Highschool Certificate or 
Equivalent (%) 21.7 23.7 20.5 
Apprentiship/Trades 
Certificate/Diploma (%) 8.1 7.4 7.6 
University Diploma or 
Degree (%) 42.5 39.1 42.2 
 
Recruitment took place for four consecutive weeks at each pharmacy, starting on 
November 18th 2013, and finishing February 28th 2014.  A total of 128 patients were 
approached to participate in the study, 52 provided informed consent and were recruited 
for the study, and 49 patients completed the entire study protocol.  Two patients 
consented to the study and performed the Medication Risk Assessment Questionnaire; 
however, they did not participate in a comprehensive medication assessment. One 
patient withdrew shortly before the scheduled comprehensive medication assessment 
due to a perceived lack of benefit. Figure 1 displays the recruitment summary. 
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Figure 1.  Patient recruitment 
 
 
 
 
 
 
 
 
 
 
6.2 Baseline Patient Characteristics 
The average age of patients who completed the study protocol was 53.9 years.  
The majority of patients were female (83.9%), highly educated and spoke English as 
their first language.  The average number of medications (prescription and non-
prescription) per patient was 7.2.  High Risk patients had an average of 11.7 
medications per patient compared with 4.6 in the Low Risk patients.  See Table 6 for a 
summary of the baseline patient characteristics.  Characteristics are also shown for 
patients in each risk category (as determined by researcher completed Medication Risk 
Assessment Questionnaires).  
 
 
 
 
 
 
 
 
 
Patients Approached 
N = 128 
Patients Consented 
N = 52 
Patients Completing Protocol 
N = 49 
Patients Not Completing 
Protocol 
N = 3 
Patients Included in Data 
Analysis 
N = 49 
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Table 6.  Baseline patient characteristics 
 Low Risk Patients High Risk Patients All Patients 
Number 31 18 49 
Mean Age  48.7 62.7 53.9 
Std. Error for Age  3.4 2.4 2.5 
Female Gender (%) 26 (83.9%) 11 (61.1%) 37 (75.5%) 
English as First 
Language (%) 29 (93.5%) 18 (100%) 47 (95.9%) 
Grade School as 
Highest Level of 
Education (%) 
0 (0%) 1 (5.6%) 1 (2.0%) 
High School as 
Highest Level of 
Education (%) 
5 (16.1%) 5 (27.8%) 10 (20.4%) 
Any Post-
Secondary as 
Highest Level of 
Education (%) 
26 (83.9%) 12 (66.7%) 38 (77.6%) 
Mean number of 
medications 4.6 11.7 7.2 
 
6.3 Level of Inter-rater Agreement of the Medication Risk Assessment 
Questionnaire 
6.3.1 Level of Agreement for Each Question and for the Medication Risk 
Assessment Questionnaire Overall 
The level of agreement between the self-administered patient responses on the 
Medication Risk Assessment Questionnaire and the “correct” responses (as determined 
by the researcher after the comprehensive medication assessment) was calculated 
separately for each of the five questions in the Medication Risk Assessment 
Questionnaire.  The inter-rater agreement was also calculated for the Medication Risk 
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Assessment Questionnaire as a whole (i.e., placement of patients into the proper overall 
risk category).  See Table 7. 
Table 7. Kappa values and the level of agreement for the Medication Risk Assessment 
Questionnaire. 
 Kappa value P value Level of 
Agreement(55) 
Question 1 0.877 <0.01 Very Good 
Question 2 0.422 <0.01 Fair 
Question 3 0.836 <0.01 Very Good 
Question 4 0.489 <0.01 Fair 
Question 5 0.912 <0.01 Very Good 
Medication Risk 
Assessment 
Questionnaire 
Overall  
0.910 <0.01 Very Good 
 
Questions 1, 3 and 5 had “Very Good” levels of agreement.  Questions 2 and 4 
had “Fair” levels of agreement.  Questions 2 and 4 (“Do you take 12 or more doses of 
medication each day?” and “Have your medications or the instructions on how to take 
them changed 4 or more times in the past year?”) appear to be more complex for 
patients to answer.  Similar levels of agreement have previously been reported for all 
five questions.(48) 
The level of agreement for the Medication Risk Assessment Questionnaire 
overall was “Very Good”, despite the fact that agreement was “Fair” on two of the five 
individual questions.  This indicates that patients have a very high likelihood to be 
categorized into the appropriate risk category (High Risk or Low Risk) based on their 
responses to the Medication Risk Assessment Questionnaire questions.  All calculated 
kappa values were statistically significant (P<0.01). 
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Only two patients (4.1%) were incorrectly categorized by the patient self-
administered Medication Risk Assessment Questionnaire.  Both patients answered 
“Yes” to less than three questions, making them Low Risk, while the researcher 
answered “Yes” to three or more questions, making the correct categorization as High 
Risk. 
6.4 Identified Drug Therapy Problems (DTPs) 
6.4.1 Number of Identified Drug Therapy Problems 
A total of 165 DTPs were identified in the 49 patients who completed the study 
protocol.  Patients who were categorized (using the researcher responses) as High Risk 
had, on average, 3.72 more DTPs per patient compared with those who were 
categorized as Low Risk (P<0.01). See Table 8. 
Table 8. Mean number of identified DTPs in Low Risk and High Risk groups 
 Number Mean 
Number of 
DTPs 
95% CI 
Low Risk 31 2.00 1.46-2.54 
High Risk 18 5.72 4.29-7.16 
 
  
6.4.2 Categorization of Identified Drug Therapy Problems 
The 165 identified DTPs were categorized into 8 different categories.  These 
categories consist of the 7 standard DTP categories as described by Cipolle and 
colleagues(13) as well as one supplementary category: “Other or Unsure”.  Those DTPs 
that were categorized into “Other or Unsure” were actual or suspected DTPs that could 
not be confirmed, largely due to a lack of information provided from the most 
responsible physician, or due to a lack of pertinent lab results. For example, one patient 
had not had any laboratory tests for over 12 months, and as such it was unable to be 
determined if the warfarin dose was correct for this patient.  Another patient was taking 
metoprolol for no clear indication, and the pharmacist was unable to determine if the 
medication was still required for this patient. See Table 9. 
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Table 9.  Drug therapy problem categories 
DTP Category Number (%) 
Requires a Drug 62 (37.6%) 
No Indication for Drug 20 (12.1%) 
Inappropriate Drug 19 (11.5%) 
Other or Unsure DTP 18 (10.9%) 
Noncompliance 16 (9.7%) 
Adverse Drug Reactions 11 (6.7%) 
Subtherapeutic Drug 11 (6.7%) 
Supratherapeutic Drug 8 (4.8%) 
Total Number of DTPs 165 (100%) 
 
6.4.3 Severity of Drug Therapy Problems 
Each identified DTP was placed into one of six severity categories using the 
Adapted Schneider Criteria for DTP Severity (See Appendix 5 for a detailed description 
of each risk category).(56)  The majority of the DTPs were “Moderate” in severity 
(53.9%), while the remainder were “Mild” in severity (46.1%).  There were no “Severe” 
DTPs identified. See Table 10. 
Table 10. Severity of identified DTPs 
 Number of DTPs in 
Low Risk Patients 
(%) 
Number of DTPs in 
High Risk Patients 
(%) 
Total DTPs (%) 
Mild 1  15 (24.2%) 6 (5.83%) 21 (12.7%) 
Mild 2  23 (37.1%) 32 (31.1%) 55 (33.3%) 
Moderate 1 24 (38.7%) 61 (59.2%) 85 (51.5%) 
Moderate 2 0 (0%) 4 (3.9%) 4 (2.4%) 
Severe 1  0 (0%) 0 (0%) 0 (0%) 
Severe 2  0 (0%) 0 (0%) 0 (0%) 
Total 62 (100%) 103 (100%) 165 (100%) 
 
All DTPs that were identified as Mild 1 were recommendations for patients who 
did not receive an influenza vaccination during the current flu season to receive 
seasonal influenza vaccines before the subsequent flu season.  Due to a shortage of 
influenza vaccine during the study period, many people were unable to receive 
influenza immunizations that season.  One example of a Mild 2 DTP that was identified 
in a study participant was a compliance issue.  The patient was frequently forgetting to 
take her prescribed oral contraception (as many as five times per month) and was 
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sexually active.  Because of this situation, there was the potential for pregnancy (which, 
for that patient, was a negative health outcome).  The pharmacist recommended a few 
compliance aids (such as placing the medication in an area where it would be clearly 
visible as part of a daily routine, and for the patient to set an medication reminder 
alarm), and discussed alternative birth control options (barrier methods, intra uterine 
devices, etc). 
An example of a Moderate 1 DTP was a patient taking meloxicam 15mg once 
daily for which they had no indication, placing them at risk for complications from this 
fairly high risk drug, with no therapeutic benefit.   The pharmacist communicated with 
the primary care physician on this matter, and recommended the medication be 
stopped.  Because the patient had been taking the medication for over 10 years 
(seemingly without a reasonable indication), there was no urgency for the physician to 
meet with the patient promptly, which would have moved the severity to a Moderate 2 
DTP. 
6.4.3.1 Comparison between groups of patients with at least one Moderate or Severe 
DTP 
In order to determine if one group experienced a higher number of clinically 
significant DTPs, the percentage of patients who were identified as having at least one 
Moderate or Severe DTP in each group were compared.  Forty-eight percent of Low 
Risk patients had at least one Moderate or Severe DTP, whereas 94.4% of High Risk 
patients had at least one Moderate or Severe DTP (P < 0.01).  See Table 11. 
Table 11.  Patients who have at least one Moderate or Severe DTP 
 Patients that have 
>1 Moderate or 
Severe DTP (%) 
Patients that have 
<1 Moderate or 
Severe DTP (%) 
Total 
Low Risk 15 (48.4%) 16 (51.6%) 31 
High Risk 17 (94.4%) 1 (5.5%) 18 
 
6.4.3.2 Overall comparison of DTP severity between groups 
The mean number of mild DTPs in Low Risk patients was 1.23 per patient 
compared with 2.11 in High Risk patients (P=0.03).  The mean number of Moderate 
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DTPs in Low Risk patients was 0.77 per patient compared with 3.61 in High Risk 
patients, a difference of 2.84 DTPs per patient (P<0.01).  See Table 12. 
 
Table 12. Overall DTP severity comparison 
 Number of 
patients 
Mean 
number 
of DTPs 
per 
patient 
Mean 
number of 
Mild DTPs 
per patient 
Mean number 
of Moderate 
DTPs per 
patient 
Mean number of 
Severe DTPs per 
patient 
Low 
Risk 
31 2.00 1.23 0.77 0.00 
High 
Risk 
18 5.72 2.11 3.61 0.00 
  P<0.01 P=0.03 P<0.01  
 
6.5 Comparison of the Medication Risk Assessment Questionnaire with the 
Eligibility Requirements of Provincial Medication Assessment Programs in 
Canada 
All patient information was analyzed to determine which patients would be 
eligible for a medication review service in each of the provinces that has such a 
program.  Table 14 reports the proportion of Low Risk and High Risk patients who 
would have been eligible for a medication review in each province. 
Table 13.  Eligibility for provincial medication review programs in Canada 
 % Low Risk 
Patients Eligible 
(n) 
% High Risk 
Patients Eligible 
(n) 
Newfoundland and 
Labrador 3.2% (1) 38.9% (7) 
PEI 32.3% (10) 100% (18) 
Nova Scotia 32.3% (10) 100% (18) 
New Brunswick 3.2% (1) 32.3% (10) 
Ontario 32.3% (10) 100% (18) 
Saskatchewan 0% (0) 32.3% (10) 
Alberta 25.8% (8) 94.4% (17) 
British Columbia 3.2% (1) 94.4% (17) 
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Prince Edward Island, Nova Scotia, Ontario and Alberta have relatively high rates 
of Low Risk patients who would be eligible for medication reviews while New Brunswick 
and Saskatchewan have relatively low proportions of High Risk patients who are eligible 
for provincial medication review services.  Newfoundland and Labrador, New 
Brunswick, Saskatchewan and British Columbia have low proportions of Low Risk 
patients who are eligible for provincial medication review services.  Prince Edward 
Island, Nova Scotia, Ontario, Alberta and British Columbia have relatively high 
proportions of High Risk patients who are eligible for medication reviews. 
The common factor for programs in Prince Edward Island, Nova Scotia and 
Ontario is that any patient taking at least three chronic medications qualifies for a 
medication review.  This threshold of three or more chronic medications makes nearly 
one third of the patients identified as Low Risk eligible for medication reviews.  In 
Alberta the eligibility criteria is similar; as patients taking three or more prescription 
medications (or two prescription medications and insulin) qualify for a Standard 
Medication Management Assessment provided they also have one of the accepted 
chronic conditions, such as hypertension, diabetes, COPD or a mental health disorder; 
which are commonly treated with prescription medications.  
In Newfoundland and Labrador, only patients taking oral hypoglycemic 
medication and/or insulin qualify for a medication review, which limits the amount of 
High Risk patients who qualify to 38.9%.  New Brunswick and Saskatchewan 
medication review programs are only available to individuals over the age of 65 
(amongst other criteria), which limits the number of High Risk patients who would have 
qualified. 
British Columbia’s Medication Review Services eligibility criteria exclude the 
majority of Low Risk patients (96.8% excluded), and accept the majority of High Risk 
patients (94.4%) due to excluding patients taking less than 5 prescription medications.   
  
42 
 
Chapter Seven - Discussion 
7.1 Research Objective 1: To determine if the Medication Risk Assessment 
Questionnaire identifies patients within a community pharmacy setting who 
have a significant number of DTPs. 
The findings of this study suggest that the Medication Risk Assessment 
Questionnaire is effective at identifying patients at high risk of DTPs, who may benefit 
from a comprehensive medication assessment.  Patients who were determined to be 
High Risk by the Medication Risk Assessment Questionnaire had significantly more 
DTPs than those who were Low Risk (5.72 vs. 2.00, P<0.01) and their DTPs were also, 
on average, more serious (63.1% of DTPs in High Risk patients were of Moderate 
severity vs. 38.7% in Low Risk patients).   
 Unfortunately there are limited published studies available for comparison with 
the results of the Medication Risk Assessment Questionnaire in this study.  Hugtenburg 
and colleagues(45)(see Chapter 2.7) found that 22.3% of patients were categorized as 
“high risk” when an in-depth community pharmacist-led interview was used as the 
screening tool, while the Medication Risk Assessment Questionnaire, categorized 
36.7% (18/49) of community pharmacy based patients as High Risk.  While it is 
impossible to draw definitive conclusions from these apparent differences in rates of 
high-risk patients in each study, because no direct comparison of the two screening 
processes has ever been performed; it suggests that the Medication Risk Assessment 
Questionnaire might be capable of identifying more high risk patients in a community 
pharmacy setting than the time intensive patient interviews used in the Hugtenburg 
study.   
The original evaluation of the Langford screening tool(11), was performed in a 
family physician clinic setting. That study found proportionally fewer high risk patients 
compared with this study (20.0% vs. 36.7%).  This could suggest that patients who 
present to a community pharmacy to refill a prescription might, on average, be at 
greater risk of experiencing DTPs compared with patients waiting for an appointment in 
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a family physician office.  However, more research is required to confirm this 
hypothesis.  
The number of DTPs identified in this study can also be compared to other 
studies in an effort to further interpret the results.  A Swiss study(19) that used overall 
drug costs to screen for high-risk patients found an average of 2.6 DTPs per high-risk 
patient and the original evaluation of the Langford questionnaire found 3.1 DTPs per 
patient.  Other studies investigating the impact of pharmacist-led comprehensive 
medication assessment programs indicate that the average number of DTPs identified 
(and/or resolved) per patient ranges from 2.3 to 4.4.(14–16)  The average number of 
DTPs in this Medication Risk Assessment Questionnaire study was 3.4 per patient, 
which is within the range previously reported in the literature.  This suggests that the 
complexity of the patients in our study was likely similar to those in other studies and 
that the pharmacist who performed the comprehensive medication assessments likely 
did a thorough job of the assessments.    
7.2 Research Objective 2:  To establish the level of agreement between the 
patient self-administered responses to the Medication Risk Assessment 
Questionnaire, and the subsequent risk categorization with the correct 
responses and categorization as determined after completion of a 
comprehensive medication assessment with a pharmacist. 
This project had three specific research objectives which each to some degree 
relied on the ability of the patient participants to correctly answer the Medication Risk 
Assessment Questionnaire, without the aid of the researcher or pharmacy staff.  The 
high level of agreement (k = 0.910) which was found between the patient self-
administered responses to the Medication Risk Assessment Questionnaire and the 
correct responses to each question (as determined from their medication records after 
completion of a comprehensive medication assessment) suggest that participants were 
able to accurately complete the Medication Risk Assessment Questionnaire without 
assistance.   
Questions 1 and 3 (see Appendix 1) may be easier to answer because they ask 
patients to determine if they meet relatively simple to calculate thresholds for numbers 
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of medications (five) and medical conditions (three).  This may partially explain the high 
Kappa values that were found for these two questions.  Question 5 asks patients to 
recognize if they are taking one or more of the 12 listed high alert/high risk medications 
or class of medications.  This question had the highest level of agreement of any 
question, with a Kappa value of 0.912.  This high Kappa value is likely due to most 
patients being able to recognize the name of the drugs they are taking when they see 
them in a list.  The high Kappa values indicate that these three questions work well and 
should not be modified in future versions of the Medication Risk Assessment 
Questionnaire. 
Questions 2 and 4 had “Fair” levels of agreement (Kappa value 0.42 and 0.489 
respectively).  Question 2 is complex as it requires patients to calculate a high threshold 
of doses of medication taken per day (12 doses), and some patients may have difficulty 
mapping out their daily dosing schedule in a short amount of time, especially without 
their medications present.  What constitutes “dose” may also be difficult to interpret for 
some patients.  For example, a patient inhaling two puffs of a metered dose inhaler may 
think of that as two doses (one dose in each puff), while others may interpret that to be 
only one dose.  Dimitrow and colleagues(49) have a similar question in their “Drug 
Related Problem (DRP) Risk Assessment Tool”, and have chosen to include a detailed 
example in the tool.  It reads “Example of counting the doses: Drug 1: 1 tablet 3 times a 
day = 3 doses, Drug 2: 1 dose 2 times a day = 2 doses, i.e., in total 5 doses a day”.  
Future versions of the Medication Risk Assessment Questionnaire could be modified to 
include similar examples to clarify what constitutes a dose, which may be helpful in 
increasing the inter-rater agreement of this question. 
Question 4 may be difficult for patients to answer accurately because it requires 
patients to think about their medication history in a comprehensive manner, and they 
may not be able to recall all the recent changes or modifications that have been made 
to their regimen.  It should also be noted that it was difficult for the researcher to answer 
this question on behalf of patients with complete certainty as this response was 
generated based solely on the medication record, which may not have complete 
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information on all of the patient’s medication changes.  It is unclear how this question 
could be modified in the future to improve its reliability.   
Despite the fact that two of the five questions had a “Fair” level of agreement, the 
Medication Risk Assessment Questionnaire assigned almost all participants to the 
correct risk group (“Very Good” level of agreement for the overall Medication Risk 
Assessment Questionnaire, Kappa value = 0.910).  These findings are consistent with 
previous evaluations of similar screening tool questions(48), confirming that the 
Medication Risk Assessment Questionnaire can be effectively self-administered by 
patients in a community pharmacy setting, with little or no assistance from pharmacy 
staff.  The high Kappa values give a large degree of confidence that the results of this 
study are trustworthy, in that the Medication Risk Assessment Questionnaire can assign 
patients to the correct risk groups based on their self-administered responses.   
 7.3 Research Objective 3: To compare the Medication Risk Assessment 
Questionnaire with the eligibility requirements of provincial medication 
review programs in Canada. 
This project was not designed nor intended to be an evaluation of the current 
medication review program eligibility criteria across Canada.  However, previously 
published research identified that the highly variable eligibility criteria of these programs 
are not evidence based and have not been formally evaluated to determine their 
effectiveness in identifying high risk patients who might benefit the most from a 
comprehensive medication assessment.(10)  Although some of the provincially funded 
medication review programs in Canada would have included the majority of the High 
Risk patients identified by the Medication Risk Assessment Questionnaire (and 
consequently not included most of the Low Risk patients), many others would have 
excluded large numbers of High Risk patients, while at the same time including many 
Low Risk patients (see Table 14).  This large discordance could indicate that not all 
provincial medication review programs are optimized to accept and reject the most 
appropriate patients.  The results of this study provide additional evidence that a formal 
evaluation of the eligibility criteria used by medication review programs in Canada is 
warranted. 
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7.4: Limitations 
There are a number of limitations to this study, including the possibility of 
researcher bias.  The researcher (RP; who recruited all patients, performed all 
comprehensive medication assessments and collected and analysed all research data), 
is a practicing pharmacist with experience working in a community pharmacy setting 
and who consequently may have had pre-conceived notions about the usefulness of 
this intervention.  In an attempt to reduce the potential impact of researcher bias on the 
results, the Medication Risk Assessment Questionnaire was completed independently 
by the patient out of sight of the researcher, and placed into a sealed envelope prior to 
returning it to the researcher.  This envelope was only opened after all comprehensive 
medication assessments were complete, and the researcher had completed Medication 
Risk Assessment Questionnaires on behalf of each patient using the information from 
the comprehensive medication assessments.  This procedure was followed to minimize 
potential researcher bias during the comprehensive medication assessment with the 
patient so that the researchers’ assessment of the number and severity of DTPs would 
not be influenced by the patient’s assigned risk category.  In addition, external auditors 
confirmed the DTP severity assessments of the primary investigator, in a further effort to 
mitigate potential researcher bias.     
One positive aspect of having the primary investigator complete all of the 
comprehensive medication assessments and identify all of the DTPs was that it was 
easier to ensure the process was as consistent as possible across all patients.  To 
further ensure that consistently high quality medication assessments were performed, a 
standard comprehensive medication assessment form was used during all 
assessments.  In addition, team therapeutic discussions were held on a regular basis to 
allow the primary investigator to discuss particularly difficult or uncertain cases with a 
group of experienced colleagues.  
Using DTPs as an endpoint in this study is also a limitation.  In previous studies, 
the identification of DTPs has not been definitively linked with an improvement in patient 
health outcomes, such as hospitalizations or emergency department visits.  However, 
this is a commonly used endpoint in pharmacy practice research studies that do not 
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have the resources or scope to measure long-term patient health outcomes.  In order to 
add greater clinical meaning to the number of DTPs identified in this study, the severity 
of the DTPs was also assessed.  Unfortunately, there is no standard method for 
assessing the severity of DTPs and the Adapted Schneider Criteria for DTP Severity 
(which was used in this research) has not been previously studied in community 
pharmacy patients, and has therefore not been validated in this setting.   
It would have been ideal to follow up on the outcomes of the DTPs identified during 
the study to determine the extent to which they were addressed by physicians and 
ultimately resolved, and the impact the identification of DTPs ultimately had on patient 
health outcomes.  However, due to the scope of this project, there was not adequate 
time or resources available to perform long-term follow-up of the identified DTPs.    
 Participating pharmacies were not selected randomly, which is another limitation 
of this study.  Pharmacies were selectively chosen for participation in this project based 
on their expected interest in, and acceptability of the intervention.  Random selection of 
pharmacies may have made the results more generalizable by having a potentially more 
representative patient sample and a pharmacy staff that was not pre-selected to be 
accepting of the intervention.  However, since the purpose of this study was to test the 
effectiveness of the Medication Risk Assessment Questionnaire (and not it’s 
acceptability to pharmacy staff nor the feasibility of implementation), it was decided to 
forgo random selection in an effort to ensure an adequate number of patients and in the 
interest of timely completion of the project.   
An additional limitation is that pharmacy staff were able to exclude patients for 
study participation who they thought would not be appropriate for any reason.  This was 
included in the methodology to reassure pharmacy staff that the intervention would not 
be bothersome to their emotionally or physically unstable patients.  Although this 
created the potential for large numbers of patients to be excluded and a 
misrepresentative sample recruited, patient exclusion by pharmacy staff occurred only 
once to the researchers knowledge (0.8% of approached patients) during the entire 
study, across all three sites (in the case of an intoxicated patient). 
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The relatively homogenous characteristics of the recruited patients also reduces 
the generalizability of the results.  Participants in this study were mostly English 
speaking (95.9% spoke English as first language), highly educated (77.6% had some 
post-secondary education) and were recruited from pharmacies surrounded by 
communities with a high average household income ($66,996 - $106,267), which is not 
representative of many areas of Saskatoon or Canada.  This may affect the 
generalizability of the results related to the ability of the patients to correctly answer the 
questions on the Medication Risk Assessment Questionnaire, because it is possible that 
less educated patients who do not speak English as their first language may have more 
difficulty answering the questionnaire independently.  It has also been shown that Non-
English speaking patients suffer from more adherence related DTPs than English 
speaking patients(60); likely due to language barrier induced comprehension issues. 
 Due to the study design there is also the potential of volunteer bias.  Previous 
research suggests that people who volunteer for research studies tend to be more 
educated and of higher social class and they may also be healthier, and may follow 
treatment plans more closely than non-volunteers.(61)  While volunteer bias may be 
unavoidable, this project made it clear to participants during the consent process, and 
during the comprehensive medication assessment that all information would remain 
confidential and anonymous, which is a cited barrier to volunteering.(61)  It is possible 
that patients who perceived the comprehensive medication assessment as valuable 
enough to participate in the study would do so because of existing concerns 
surrounding their medications or medical conditions, however this view was never 
conveyed to the researcher.  Due to the steps taken to ensure that all patient 
recruitment activities highlighted the confidential nature of the study procedure and the 
lack of expressed patient concerns regarding their medications prior to the 
comprehensive medication assessment, the potential for volunteer bias was minimized.   
7.5 Future research 
 Although the findings of this study suggest that the Medication Risk Assessment 
Questionnaire is effective at identifying patients at high risk of DTPs (and those whose 
DTPs are of greater severity) who may benefit the most from a comprehensive 
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medication assessment, the optimal threshold of “Yes” responses for identifying high 
risk patients remains unknown.  This study used a threshold of three “Yes” responses to 
categorize High Risk patients based on the threshold used in previous research.(11,48)  
This threshold was arbitrarily selected in previous studies and it is possible that an 
alternative threshold may be more effective at differentiating patients at highest risk for 
serious DTPs.  A subsequent study that could recruit a sufficient number of patients 
would help to answer this research question. 
 Further research is also required to determine if the Medication Risk Assessment 
Questionnaire would be feasible to integrate into typical community pharmacy practice.  
Considering that the Medication Risk Assessment Questionnaire is quick for patients to 
complete (under 2 minutes(11)), it requires little or no help from pharmacy staff, and the 
results can be interpreted (and patient’s assigned to risk categories) quickly and easily 
by non-pharmacists, it is certainly possible that it could be successfully implemented in 
this setting.  However, community pharmacy workflow is complex and implementing 
even small changes such as implementing a short interview upon patient refill 
request(45) can be a challenge.   
 This research project was able to determine that in some provinces High Risk 
patients would not qualify for a medication review.  Conversely, many of the Low Risk 
patients would qualify for a medication review in some provinces.  A future evaluation of 
the current provincial medication review programs could help to determine the number 
and types of DTPs that are being identified, as well as the clinical significance of those 
DTPs.  These results could then be compared to the results of this study, and the 
analysis may be used to better inform the provinces on which eligibility criteria might be 
best to identify patients that community pharmacists should target to optimize efficiency 
of these services. 
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Chapter Eight – Conclusions 
The five question Medication Risk Assessment Questionnaire tested in this 
research study has been proven to have a Very Good level of agreement (k = 0.910) 
between patient self-administered responses and researcher responses after a 
comprehensive medication assessment.  This strong level of agreement indicates that 
patients are able to complete the Medication Risk Assessment Questionnaire correctly, 
and that the results of the self-assessment can be trusted for most patients. 
The Medication Risk Assessment Questionnaire is effective at identifying patients 
at high risk of DTPs, who may benefit from a comprehensive medication assessment in 
a community pharmacy setting.  Patients identified as High Risk by the Medication Risk 
Assessment Questionnaire had significantly more DTPs (mean of 5.72 DTPs vs. 2.00 in 
Low Risk patients (P<0.01)), and significantly more Moderate or Severe DTPs (3.61 
Moderate or Severe DTPs per patient vs. 0.77 Moderate or Severe DTPs in Low Risk 
patients (P<0.01)).  Consequently, patients identified as High Risk using the Medication 
Risk Assessment Questionnaire would be ideal targets for community pharmacists who 
are performing comprehensive medication assessments. 
Overall, the Medication Risk Assessment Questionnaire tested in this research 
study can be answered correctly by patients and it identifies High Risk patients who 
have numerous DTPs.  It may be a useful tool for community pharmacies looking to 
expand their practice to include comprehensive medication assessments. 
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Appendix 1 – Medication Risk Assessment Questionnaire 
Medication Risk Assessment Questionnaire 
 
Please complete all of the questions below to the best of your ability. 
 
1) Do you take 5 or more different medications on a regular basis? 
(including prescription and non-prescription products, vitamins and herbals) 
 
 
2) Do you take 12 or more doses of medication each day? 
 
 
3) Are you currently taking medications for 3 or  
more medical conditions? 
 
 
4) Have your medications or the instructions on how to  
take them changed 4 or more times in the past year? 
 
 
5) Do you take any of the following medications? 
  
Carbamazepine (Tegretol®) 
  Phenytoin (Dilantin®) 
  Warfarin (Coumadin®) 
Rivaroxaban (Xarelto®) 
Dabigatran (Pradax®) 
Apixaban (Eliquis®) 
Any drug for chronic pain  
Insulin (any type) 
Drugs to lower blood sugar 
Methotrexate 
Lithium (Carbolith®) 
Digoxin (Lanoxin®)
 
When you have completed the questionnaire, please return it to the researcher. 
 
Thank You 
 
 
Yes               No 
Yes               No 
Yes                No 
Yes                No 
Yes                No 
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Appendix 2 – Patient Characteristics Questionnaire 
Patient Characteristics 
Please complete all of the questions below to the best of your ability. 
 
What is your age?    ______ 
 
Gender:   
 
Is English your first language?  
 
What is the highest level of education you have completed? 
 
 
When you have completed the questionnaire, please return it to the researcher. 
 
Thank You 
 
 
 
 
 
 
Male Female 
Yes              No 
Grade School High School 
 
Any Post-Secondary education 
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Appendix 3: Medication Review Form 
Medication Review Form 
                           
Date: ____, 2013____ 
                                                                                               Location: ______ 
 
D
em
og
ra
ph
ic
s 
Wt Ht Age  
Occupation 
 
Living arrangement 
 
 
Health insurance (coverage issues and affordability of meds) 
 
 
 
A
lle
rg
ie
s a
nd
 A
le
rt
s Medication allergies (describe reaction and when experienced) 
 
Past adverse reactions (describe reaction and when experienced) 
 
 
 
 
 
 
 What is the pts’ primary concern about their medications? 
 
 
 
 
To what extent does the pt understand their medications? 
 
 
 
So
ci
al
 d
ru
gs
 
Smoking / tobacco? 
 
 
Caffeine? 
 
Alcohol / Recreational drug use? 
 
 
PM
H
 Relevant past medical history 
 
 
 
Patient information 
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  Meds Taken in past (include why and when stopped) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Current Medications (Rx, OTC, Herbals) 
 
 
 
 
 
 
 
 
 
 
 
 
Drug Therapy Problems to investigate 
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Remind pt that you need to ask a series of ‘yes/no’ questions to make sure you didn’t miss anything in your assessment 
and to screen for side effects to their medications 
R
ev
ie
w
 o
f S
ys
te
m
s 
EENT (vision, hearing, or nasal problems; coughing) 
 
Cardio (chest pain, heart problems, HTN, lipids) 
 
Pulmonary (breathing problems) 
 
 
GI (stomach problems or pain, nausea, constipation, trouble swallowing) 
 
 
Skin (any skin troubles) 
 
 
Endocrine (diabetes, thyroid history) 
   
 
Hepatic (any history of liver problems) 
 
 
Diet  (general diet, weight changes) 
 
 
Reproductive (incontinence, impotence, hot flashes) 
 
 
Renal / urinary (urinary frequency, renal dysfunction) 
 
 
Hematology (bruising, bleeding) 
 
 
MSK (pain) 
 
Neuro (numbness, tingling, balance or falls, memory) 
 
 
Psych (mood) 
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ID (any infectious diseases like HIV, Hep C, TB, etc) 
 
Immunizations 
   Influenza ()   Pneumovax   
   Other____________________ 
Any additional diagnoses not discussed? 
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Appendix 4: Langford Screening Questionnaire 
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Appendix 5 – Adapted Schneider Criteria for DTP Severity 
0. 
 Severity Evaluation Pharmaceutical Intervention in Primary Care 
Category DTP 
Status 
With patient and/
or 
With health care professionals 
Mild 1 A DTP 
occurred in 
the past. 
Pharmacist provides advice 
to prevent the subsequent 
occurrence of the DTP. 
Pharmacist may provide information on patient’s 
medications and other relevant information to the 
patient’s circle of care. 
Mild 2 A DTP is 
present. 
Pharmacist provides 
specific advice to resolve 
the DTP. 
Pharmacist communicates with the patient’s health care 
team and/or issues a pharmaceutical opinion to 
recommend a change in pharmacotherapy. 
Moderate 1 A DTP is 
present. 
Pharmacist provides 
specific advice to resolve 
the DTP and carries out a 
monitoring plan of specific 
symptoms. 
Pharmacist communicates with the patient’s health care 
team and/or issues a pharmaceutical opinion to 
recommend a change in pharmacotherapy.  Pharmacist 
suggests a monitoring plan, specific to vital signs or 
laboratory tests. 
Moderate 2 
 
A DTP is 
present. 
Pharmacist provides 
specific advice to resolve 
the DTP and carries out a 
monitoring plan of specific 
symptoms.  Pharmacist 
recommends to patient to 
visit his/her physician 
quickly 
Pharmacist communicates with the patient’s health care 
team and/or issues a pharmaceutical opinion to 
recommend a change in pharmacotherapy quickly.  If 
needed, pharmacist can suggest the physician to meet 
the patient promptly or communicate with the health 
care team in order to follow up vital signs and/or ask for 
laboratory tests. 
Severe 1 A DTP is 
present. 
Pharmacist recommends to 
patient to go to the 
Emergency Room 
immediately 
 
Severe 2 A DTP is 
present. 
Pharmacist calls 911 for 
the patient to be conducted 
to the Emergency Room 
immediately. 
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